Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

netupitant

Known as: 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide, 2-[3,5-bis(Trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide 
A selective neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. Netupitant competitively binds to and blocks the activity of… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
This study was designed to determine the appropriate clinical dose of netupitant (NETU), a new NK1 receptor antagonist (RA), to… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
NEPA is an oral single, fixed-dose combination of netupitant, a new highly selective NK1 RA and palonosetron (PALO), a… Expand
  • figure 1
  • figure 3
  • table 1
  • table 3
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
In this multinational, phase III study, the safety and efficacy of NEPA, a convenient, fixed-dose antiemetic combination of… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2014
2014
Netupitant is a new, selective NK1 receptor antagonist under development for the prevention of chemotherapy-induced nausea and… Expand
  • figure 1
  • figure 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Current therapy for chemotherapy-induced nausea and vomiting includes the use of both 5-HT3 and NK1 receptor antagonists. Acute… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
2014
2014
Chemotherapy-induced nausea and vomiting is ranked among the worst side effects of chemotherapy. NEPA is an oral fixed-dose… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2013
2013
PurposeNetupitant is a new highly selective neurokinin-1 receptor antagonist being studied for the prevention of nausea and… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2013
2013
ObjectivesNeurokinin-1 receptor antagonists (NK1 RAs) are commonly coadministered with a 5-HT3 RA such as palonosetron to prevent… Expand
  • table 1
  • table 3
  • table 4
  • table 5
  • table 6
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Netupitant is a potent and selective NK(1) receptor antagonist under development in combination with a fixed dose of palonosetron… Expand
Is this relevant?
2012
2012
The novel NK(1) receptor ligand Netupitant has been characterized in vitro and in vivo. In calcium mobilization studies CHO cells… Expand
Is this relevant?